• Bin Cao, Qian Wang, Xiao-Li Fu, Guo-Dong Wei, Long Zhao, Pei-Jun Zhang, Dairong Li, Hui-Qing Zhang, and Qi Zhang.
• Department of the Third General Surgery, Baoding First Central Hospital, Baoding Key Laboratory of Gastrointestinal Diagnosis and Treatment, China.
• Medicine (Baltimore). 2021 Dec 17; 100 (50): e27709e27709.

IntroductionThe efficacy of neoadjuvant nimotuzumab for gastric cancer remained controversial. We conducted a systematic review and meta-analysis to explore the efficacy of neoadjuvant nimotuzumab plus chemotherapy vs chemotherapy for gastric cancer.MethodsWe have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through May 2019, and included randomized controlled trials assessing the efficacy of neoadjuvant nimotuzumab plus chemotherapy vs chemotherapy for gastric cancer. This meta-analysis was performed using the random-effect model.ResultsFour randomized controlled trials were included in the meta-analysis. There were 128 patients included in intervention group and 131 patients included in control group. Overall, compared with chemotherapy for gastric cancer, neoadjuvant nimotuzumab plus chemotherapy showed no substantial influence on response rate (risk ratio [RR] = 1.22; 95% CI = 0.78-1.89; P = .38), disease control rate (RR = 2.22; 95% confidence interval [CI] = 0.32-15.40; P = .42), rash (RR = 1.26; 95% CI = 0.96-1.66; P = .10), neutropenia (RR = 1.26; 95% CI = 0.96-1.66; P = .10), anemia (RR = 1.08; 95% CI = 0.62-1.89; P = .78), or nausea (RR = 1.19; 95% CI = 0.96-1.48; P = .12), but might improve the incidence of vomiting (RR = 1.60; 95% CI = 1.03-2.50; P = .04).ConclusionsNeoadjuvant nimotuzumab might provide no additional benefits to the treatment of gastric cancer.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…